#1 Clinical Trials Search in Europe

E2814

E2814 is an investigational drug currently being studied in clinical trials for its potential to treat Alzheimer’s disease. This article provides an overview of the ongoing research into E2814, including its safety, efficacy, and potential benefits for patients with early-stage Alzheimer’s and those at risk for inherited forms of the disease.

Table of Contents

What is E2814?

E2814 is an investigational drug being studied as a potential treatment for Alzheimer’s disease[1]. It is a type of medication called an antibody, which is designed to target specific proteins in the body. In this case, E2814 targets a protein called tau, which is believed to play a role in the development of Alzheimer’s disease[2].

How E2814 Works

E2814 works by binding to a specific part of the tau protein called the microtubule-binding region (MTBR)[2]. This region is important because it’s involved in the formation of tau aggregates, which are clumps of tau protein that can damage brain cells. By binding to this region, E2814 aims to disrupt the formation of these harmful aggregates and potentially slow down the progression of Alzheimer’s disease[3].

Conditions Treated by E2814

E2814 is primarily being studied for the treatment of Alzheimer’s disease, including:

  • Early Alzheimer’s disease: This refers to the early stages of the condition when symptoms are mild[4].
  • Dominantly Inherited Alzheimer’s Disease (DIAD): This is a rare form of Alzheimer’s caused by specific genetic mutations[3].

Clinical Trials Involving E2814

Several clinical trials are currently underway to evaluate the safety and effectiveness of E2814:

  • Phase 1 studies: These early studies are assessing the safety, tolerability, and how the drug moves through the body (pharmacokinetics) in healthy volunteers[1].
  • Phase 1b/2 studies: These trials are evaluating E2814 in people with mild to moderate cognitive impairment due to Alzheimer’s disease[2].
  • Phase 2/3 studies: Larger trials are investigating the potential benefits of E2814 in combination with other Alzheimer’s treatments[3][4].

How E2814 is Administered

E2814 is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. In clinical trials, it’s typically administered every four weeks (Q4W)[1][4]. The exact dosage and frequency may vary depending on the specific trial and treatment plan.

E2814 in Combination Therapy

Some clinical trials are studying E2814 in combination with another drug called lecanemab (also known as BAN2401)[3][4]. Lecanemab is an antibody that targets a different protein involved in Alzheimer’s disease called amyloid. The goal of combining these treatments is to potentially enhance their effectiveness by targeting multiple aspects of the disease process.

Safety and Side Effects

As E2814 is still in clinical trials, its full safety profile and potential side effects are not yet fully known. The ongoing studies are carefully monitoring participants for:

  • Treatment-emergent adverse events (TEAEs): These are any new medical problems or worsening of existing problems that occur during treatment[1].
  • Serious adverse events (SAEs): These are more severe or life-threatening side effects[1].
  • Changes in laboratory values, vital signs, and electrocardiogram (ECG) findings[1].
  • Development of antibodies against E2814, which could potentially affect its effectiveness[1].
It’s important to note that as an investigational drug, E2814 is not yet approved for general use and is only available through clinical trials. Patients interested in learning more about E2814 should consult with their healthcare providers and consider participating in clinical trials if eligible.

Aspect Details
Drug Name E2814
Target Tau protein in Alzheimer’s disease
Administration Intravenous infusion, typically every 4 weeks
Patient Population Early Alzheimer’s disease, including mild to moderate cognitive impairment; some studies focus on dominantly inherited Alzheimer’s disease (DIAD)
Study Objectives Safety, tolerability, pharmacokinetics, pharmacodynamics, biomarker effects, cognitive outcomes
Combination Therapy Some trials studying E2814 in combination with lecanemab (anti-amyloid drug)
Key Measurements Cerebrospinal fluid (CSF) tau levels, tau PET imaging, cognitive assessments, safety parameters
Trial Phases Phase 1, 2, and 2/3 studies ongoing

FAQ

  • What is E2814? E2814 is an investigational drug being studied for its potential to treat Alzheimer's disease. It is designed to target tau protein, which is believed to play a role in the progression of Alzheimer's.
  • How is E2814 administered? E2814 is administered through intravenous (IV) infusion, typically every four weeks.
  • What types of Alzheimer's patients are being studied with E2814? Clinical trials are studying E2814 in patients with early Alzheimer's disease, including those with mild to moderate cognitive impairment. Some studies are also focusing on individuals with dominantly inherited Alzheimer's disease (DIAD), a rare genetic form of the condition.
  • Is E2814 being studied alone or in combination with other treatments? While some trials are studying E2814 alone, others are investigating its use in combination with other Alzheimer's treatments, such as lecanemab, an anti-amyloid drug.
  • What are researchers hoping to learn from these clinical trials? Researchers are assessing the safety and tolerability of E2814, as well as its effects on various biomarkers associated with Alzheimer's disease. They are also studying its potential to slow cognitive decline and improve clinical outcomes in patients.

Ongoing Clinical Trials on E2814

  • Study on Lecanemab and Drug Combination for Patients with Early Onset Alzheimer’s Disease Due to Genetic Mutation

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Ireland Italy The Netherlands Spain

Glossary

  • Alzheimer's disease: A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Tau protein: A protein found in neurons that can form abnormal tangles in the brains of people with Alzheimer's disease.
  • Biomarker: A measurable substance in the body that can indicate the presence or progression of a disease or the effects of treatment.
  • Cerebrospinal fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, often used to measure biomarkers in Alzheimer's research.
  • Dominantly Inherited Alzheimer's Disease (DIAD): A rare form of Alzheimer's caused by specific genetic mutations that almost guarantee development of the disease, typically at a younger age than typical Alzheimer's.
  • Cognitive impairment: A decline in mental abilities such as memory, thinking, and reasoning.
  • Intravenous (IV) infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical effects.

References

  1. https://clinicaltrials.gov/study/NCT04231513
  2. https://clinicaltrials.gov/study/NCT04971733
  3. https://clinicaltrials.gov/study/NCT05269394
  4. https://clinicaltrials.gov/study/NCT06602258
  5. https://clinicaltrials.eu/trial/study-on-lecanemab-and-drug-combination-for-patients-with-early-onset-alzheimers-disease-due-to-genetic-mutation/